Clinical Trial Update: Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC [Phase 1]

View source ↗

Summary

A Phase 1 study assessing adjuvant rapamycin to prevent recurrence after treatment of early-stage hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: Eastern Hepatobiliary Surgery Hospital | Conditions: Hepatocellular Carcinoma, Rapamycin | Phase 1 | Status: COMPLETED